The Nitric Oxide Synthase Inducible pipeline drugs market research report outlays comprehensive information on the Nitric Oxide Synthase Inducible targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Nitric Oxide Synthase Inducible pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Respiratory, Immunology, Musculoskeletal Disorders, and Oncology which include the indications Acute Respiratory Distress Syndrome, Idiopathic Pulmonary Fibrosis, Inflammation, Systemic Sclerosis (Scleroderma), Musculoskeletal Disorders, Arthritis, Brain Cancer, and Malignant Glioma. It also reviews key players involved in Nitric Oxide Synthase Inducible targeted therapeutics development with respective active and dormant or discontinued products.
The Nitric Oxide Synthase Inducible pipeline targets constitutes close to nine molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, and Preclinical stages are 2, and 4 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 2 molecule.
Nitric Oxide Synthase Inducible overview
Nitric Oxide Synthase Inducible is also known as Inducible Nitric Oxide Synthase (iNOS). Inducible Nitric Oxide Synthase is an enzyme that in humans is encoded by a gene NOS2. This enzyme is responsible for the synthesis of nitric oxide (NO). iNOS is one of the three isoforms of nitric oxide synthase, alongside endothelial NOS (eNOS) and neuronal NOS (nNOS). iNOS is inducible means its expression and activity are increased in response to various stimuli, such as inflammatory cytokines, bacterial products, and other immune signals. iNOS catalyzes the conversion of L-arginine to nitric oxide (NO) and citrulline. NO is a versatile signaling molecule that plays roles in vasodilation, immune response, neurotransmission, and other physiological processes. Excessive NO production may lead to the formation of reactive nitrogen species, contributing to oxidative stress and tissue damage.
For a complete picture of Nitric Oxide Synthase Inducible’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
